#United States #San Francisco #Immuno-Oncology #Leap Therapeutics #DKN-01

Leap Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics, Inc. (NASDAQ: LPTX), a key player in the biotechnology sector focusing on targeted and immuno-oncology therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. This prestigious event is scheduled to take place in San Francisco, California, on January 15, 2025.

Presentation Details

Douglas E. Onsi, the President and CEO of Leap Therapeutics, will deliver a comprehensive corporate overview during the conference. The presentation is set for 2:15 p.m. Pacific Time. Attendees and interested parties will be able to access a live webcast of the presentation through the Investors page of the company's website. A replay of the event will also be available for a limited time after the live broadcast.

About Leap Therapeutics

Leap Therapeutics specializes in the development of innovative therapeutics for cancer treatment. Among its most notable clinical candidates is DKN-01, a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein. DKN-01 is currently under development for treating several forms of cancer, including esophagogastric, colorectal, and gynecological cancers.

In addition to DKN-01, Leap's pipeline includes FL-501, another humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, which is currently in preclinical development.

Importance of the J.P. Morgan Healthcare Conference

The J.P. Morgan Healthcare Conference is one of the most significant events in the healthcare industry, attracting investors and healthcare professionals from all over the world. It serves as a prime platform for companies to showcase their innovations, share insights about their pipeline developments, and engage with potential investors. By participating in such a high-profile conference, Leap Therapeutics aims to enhance its visibility and outline its commitment to advancing the field of cancer therapeutics.

How to Attend

For those interested in the live presentation, further details are available on Leap Therapeutics' official website. The webcast can be found on the Investors page, providing a unique opportunity for individuals unable to attend the conference in person to gain insights directly from company leadership.

Conclusion

Leap Therapeutics is strategically positioned to leverage this conference to expand its reach and inform stakeholders about its pioneering work in the biotechnology arena. With promising candidates like DKN-01 and a strong leadership team, the company continues to forge ahead in the competitive landscape of oncology therapeutics. For further inquiries or information, please refer to their official website or investor relations contacts.

For more information about Leap Therapeutics, visit their official website or view their public filings with the SEC through EDGAR at SEC website.